This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Michaelson, M. D. Articles by Smith, M. R. Search for Related Content PubMed PubMed Citation Articles by Michaelson, M. D. Articles by Smith, M. R.

Bisphosphonates for Treatment and Prevention of Bone Metastases

M. Dror Michaelson, Matthew R. Smith

From the Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA

Address reprint request to Matthew R. Smith, MD, PhD, Massachusetts General Hospital, Cox 640, 100 Blossom St, Boston, MA 02114; e-mail: smith.matthew{at}mgh.harvard.edu.

Bone metastases are a major cause of morbidity for men with prostate cancer. Complications of bone metastases include pain, fractures, and spinal cord compression. Although they appear osteoblastic by radiographic imaging, most bone metastases are characterized by excess osteoclast number and activity. In addition, pathologic osteoclast activation is associated with increased risk of skeletal complications. Zoledronic acid, a potent inhibitor of osteoclast activity, differentiation, and survival, decreases the risk of skeletal complications in men with androgen-independent prostate cancer and bone metastases. Other bisphosphonates, including pamidronate and clodronate, seem to be ineffective in this setting. The reduction in risk of skeletal complications with zoledronic acid must be weighed against potential adverse effects. Additional studies are needed to determine the optimal timing, schedule, and duration of treatment in men with bone metastases as well as the potential role of bisphosphonates in other settings including the prevention of bone metastases.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				A. Kyrgidis, K. Vahtsevanos, G. Koloutsos, C. Andreadis, I. Boukovinas, Z. Teleioudis, A. Patrikidou, and S. Triaridis Bisphosphonate-Related Osteonecrosis of the Jaws: A Case-Control Study of Risk Factors in Breast Cancer Patients J. Clin. Oncol., October 1, 2008; 26(28): 4634 - 4638. [Abstract] [Full Text] [PDF]

				S.-H. Lin, Y.-C. Lee, M. B. Choueiri, S. Wen, P. Mathew, X. Ye, K.-A. Do, N. M. Navone, J. Kim, S.-M. Tu, et al. Soluble ErbB3 Levels in Bone Marrow and Plasma of Men with Prostate Cancer Clin. Cancer Res., June 15, 2008; 14(12): 3729 - 3736. [Abstract] [Full Text] [PDF]

				S.L. Ruggiero and S.J. Drew Osteonecrosis of the Jaws and Bisphosphonate Therapy J. Dent. Res., November 1, 2007; 86(11): 1013 - 1021. [Abstract] [Full Text] [PDF]

				J. Sonnemann, B. Bumbul, and J. F. Beck Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro Mol. Cancer Ther., November 1, 2007; 6(11): 2976 - 2984. [Abstract] [Full Text] [PDF]

				H. Peng, Y. Sohara, R. A. Moats, M. D. Nelson Jr., S. G. Groshen, W. Ye, C. P. Reynolds, and Y. A. DeClerck The Activity of Zoledronic Acid on Neuroblastoma Bone Metastasis Involves Inhibition of Osteoclasts and Tumor Cell Survival and Proliferation Cancer Res., October 1, 2007; 67(19): 9346 - 9355. [Abstract] [Full Text] [PDF]

				M. D. Mason, M. R. Sydes, J. Glaholm, R. E. Langley, R. A. Huddart, M. Sokal, M. Stott, A. C. Robinson, N. D. James, M. K. B. Parmar, et al. Oral Sodium Clodronate for Nonmetastatic Prostate Cancer--Results of a Randomized Double-Blind Placebo-Controlled Trial: Medical Research Council PR04 (ISRCTN61384873) J Natl Cancer Inst, May 16, 2007; 99(10): 765 - 776. [Abstract] [Full Text] [PDF]

				G. Kroemer, L. Galluzzi, and C. Brenner Mitochondrial Membrane Permeabilization in Cell Death Physiol Rev, January 1, 2007; 87(1): 99 - 163. [Abstract] [Full Text] [PDF]

				M. Papotti, T. Kalebic, M. Volante, L. Chiusa, E. Bacillo, S. Cappia, P. Lausi, S. Novello, P. Borasio, and G. V. Scagliotti Bone Sialoprotein Is Predictive of Bone Metastases in Resectable Non-Small-Cell Lung Cancer: A Retrospective Case-Control Study J. Clin. Oncol., October 20, 2006; 24(30): 4818 - 4824. [Abstract] [Full Text] [PDF]

				J. Liao, A. Schneider, N. S. Datta, and L. K. McCauley Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res., September 15, 2006; 66(18): 9065 - 9073. [Abstract] [Full Text] [PDF]

				G. Ferretti, A. Fabi, P. Carlini, P. Papaldo, A. Felici, F. Cognetti, and P. Vihinen What is the biological significance of circulating blood levels of metalloproteinases? Clin. Cancer Res., June 1, 2006; 12(11): 3550 - 3551. [Full Text] [PDF]

				E. J. Small and E. A. Klein Challenges and Future Directions in the Prevention and Management of Prostate Cancer J. Clin. Oncol., November 10, 2005; 23(32): 8143 - 8145. [Full Text] [PDF]